Abstract
The aims were to determine the biodistribution, translocation, and persistence of nanoceria in the brain and selected peripheral organs. Nanoceria is being studied as an anti-oxidant therapeutic. Five, 15, 30, or 55 nm ceria was iv infused into rats which were terminated 1, 20, or 720 h later. Cerium was determined in blood, brain, liver, and spleen. Liver and spleen contained a large percentage of the dose, from which there was no significant clearance over 720 h, associated with adverse changes. Very little nanoceria entered brain parenchyma. The results suggest brain delivery of nanoceria will be a challenge.
FROM THE CLINICAL EDITOR: This team of investigators revealed that nanoceria, which is being studied as an anti-oxidant, has very limited uptake by the brain regardless of the range of sizes studied, suggesting major challenges in the application of this novel approach in the central nervous system.
Document Type
Article
Publication Date
4-2013
Digital Object Identifier (DOI)
https://doi.org/10.1016/j.nano.2012.08.002
Funding Information
Sources of support: This work was supported by United States Environmental Protection Agency Science to Achieve Results [grant number RD-833772].
Repository Citation
Yokel, Robert A.; Tseng, Michael T.; Dan, Mo; Unrine, Jason M.; Graham, Uschi M.; Wu, Peng; and Grulke, Eric A., "Biodistribution and Biopersistence of Ceria Engineered Nanomaterials: Size Dependence" (2013). Pharmaceutical Sciences Faculty Publications. 186.
https://uknowledge.uky.edu/ps_facpub/186
Notes/Citation Information
Published in Nanomedicine, v. 9, issue 3.
Copyright © 2013 Elsevier Inc.
© 2013. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/.
The document available for download is the authors' post-peer-review final draft of the article.